 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Crucell N.V.
 |
Crucell N.V. |
 |
 |
 |
PROFILE |
 |
Crucell wants to be crucial to drug development. The firm produces the PER.C6 cell line from human fetal cells "immortalized" by the injection of code that causes indefinite replication. Crucell licenses PER.C6 to such drug giants as Aventis, Merck & Co., Pfizer, and Novartis. The company also licenses its MAbstract phage antibody-display library, a collection of billions of antibody fragment-bearing phages, or bacteria killers, derived from human cells. In addition to its technology, the firm is developing its own drugs, dubbed "huMADE" since they are based on human biotechnology. Crucell was formed by the 2000 merger of Dutch firms IntroGene and U-BiSys.
COMPETITION |
 |
Dyax Corp. (DYAX)
Medarex, Inc. (MEDX)
Protein Design Labs, Inc. (PDLI)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 6.50
1-Yr. Sales Growth: 103.1%
Employees: 130
Revenue per employee: $50,000.00
KEY PEOPLE |
 |
Domenico Valerio
CEO
Leonard Kruimer
CFO
CONTACT INFO |
 |
Archimedesweg 4
2333 CN Leiden, The Netherlands
Phone: 31-071-524-8701
Fax: 31-071-524-8702
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |